Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017 (2017), Article ID 7935406, 8 pages
https://doi.org/10.1155/2017/7935406
Research Article

Evaluation of Cholinergic Deficiency in Preclinical Alzheimer’s Disease Using Pupillometry

1Commonwealth Scientific and Industrial Research Organisation (CSIRO), Perth, WA, Australia
2Australian e-Health Research Centre, Perth, WA, Australia
3Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia
4Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia
5The Mental Health Research Institute (MHRI), University of Melbourne, Melbourne, VIC, Australia
6National Ageing Research Institute, Melbourne, VIC, Australia
7School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
8Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia
9School of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
10School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia

Correspondence should be addressed to Shaun Frost; ua.orisc@tsorf.nuahs

Received 28 April 2017; Accepted 4 June 2017; Published 15 August 2017

Academic Editor: Alejandro Cerviño

Copyright © 2017 Shaun Frost et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. E. Loewenfeld, The Pupil: Anatomy, Physiology, and Clinical Applications, 1999.
  2. H. Guyton, Textbook of Medical Physiology, W.B. Saunders Company Publications, Philadelphia, 9th edition, 1996.
  3. D. F. Fotiou, C. G. Brozou, A. B. Haidich et al., “Pupil reaction to light in Alzheimer’s disease: evaluation of pupil size changes and mobility,” Aging Clinical and Experimental Research, vol. 19, no. 5, pp. 364–371, 2007. View at Google Scholar
  4. F. Fotiou, K. N. Fountoulakis, M. Tsolaki, A. Goulas, and A. Palikaras, “Changes in pupil reaction to light in Alzheimer’s disease patients: a preliminary report,” International Journal of Psychophysiology, vol. 37, no. 1, pp. 111–120, 2000. View at Google Scholar
  5. E. Granholm, S. Morris, D. Galasko, C. Shults, E. Rogers, and B. Vukov, “Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer’s and Parkinson’s disease,” International Journal of Psychophysiology, vol. 47, no. 2, pp. 95–115, 2003. View at Google Scholar
  6. E. Ferrario, M. Molaschi, L. Villa, O. Varetto, C. Bogetto, and R. Nuzzi, “Is videopupillography useful in the diagnosis of Alzheimer’s disease?” Neurology, vol. 50, no. 3, pp. 642–644, 1998. View at Google Scholar
  7. A. Tales, T. Troscianko, D. Lush, J. Haworth, G. K. Wilcock, and S. R. Butler, “The pupillary light reflex in aging and Alzheimer’s disease,” Aging (Milano), vol. 13, no. 6, pp. 473–478, 2001. View at Google Scholar
  8. S. Frost, Y. Kanagasingam, H. Sohrabi et al., “Pupil response biomarkers for early detection and monitoring of Alzheimer’s disease,” Current Alzheimer Research, vol. 10, no. 9, pp. 931–939, 2013c. View at Google Scholar
  9. D. F. Fotiou, V. Stergiou, D. Tsiptsios, C. Lithari, M. Nakou, and A. Karlovasitou, “Cholinergic deficiency in Alzheimer’s and Parkinson’s disease: evaluation with pupillometry,” International Journal of Psychophysiology, vol. 73, no. 2, pp. 143–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Davies and A. J. Maloney, “Selective loss of central cholinergic neurons in Alzheimer’s disease,” Lancet, vol. 2, no. 8000, p. 1403, 1976. View at Google Scholar
  11. K. Herholz, S. Weisenbach, G. Zündorf et al., “In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease,” NeuroImage, vol. 21, no. 1, pp. 136–143, 2004. View at Google Scholar
  12. H. Tohgi, T. Abe, K. Hashiguchi, M. Saheki, and S. Takahashi, “Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia,” Neuroscience Letters, vol. 177, no. 1-2, pp. 139–142, 1994. View at Google Scholar
  13. R. Prettyman, P. Bitsios, and E. Szabadi, “Altered pupillary size and darkness and light reflexes in Alzheimer’s disease,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 62, no. 6, pp. 665–668, 1997. View at Google Scholar
  14. Alzheimer's Disease International, The Global Impact of Dementia 2013–2050, 2013.
  15. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Fagan, M. A. Mintun, R. H. Mach et al., “Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans,” Annals of Neurology, vol. 59, no. 3, pp. 512–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Sunderland, G. Linker, N. Mirza et al., “Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease,” Journal of the American Medical Association, vol. 289, no. 16, pp. 2094–2103, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. L. J. Thal, K. Kantarci, E. M. Reiman et al., “The role of biomarkers in clinical trials for Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 20, no. 1, pp. 6–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. C. Morris, C. M. Roe, E. A. Grant et al., “Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease,” Archives of Neurology, vol. 66, no. 12, pp. 1469–1475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. C. Rowe, K. A. Ellis, M. Rimajova et al., “Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging,” Neurobiology of Aging, vol. 31, no. 8, pp. 1275–1283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. V. L. Villemagne, S. Burnham, P. Bourgeat et al., “Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study,” Lancet Neurology, vol. 12, no. 4, pp. 357–367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Ellis, A. I. Bush, D. Darby et al., “The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease,” International Psychogeriatrics, vol. 21, no. 4, pp. 672–687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E. M. Stadlan, “Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Google Scholar
  24. R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, “Mild cognitive impairment: clinical characterization and outcome,” Archives of Neurology, vol. 56, no. 3, pp. 303–308, 1999. View at Google Scholar
  25. B. Winblad, K. Palmer, M. Kivipelto et al., “Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment,” Journal of Internal Medicine, vol. 256, no. 3, pp. 240–246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Bourgeat, G. Chételat, V. L. Villemagne et al., “Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia,” Neurology, vol. 74, no. 2, pp. 121–127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Vandenberghe, K. Van Laere, A. Ivanoiu et al., “18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial,” Annals of Neurology, vol. 68, no. 3, pp. 319–329, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Thurfjell, J. Lilja, R. Lundqvist et al., “Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads,” Journal of Nuclear Medicine, vol. 55, no. 10, pp. 1623–1628, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Villemagne, K. Pike, M. Fodero-Tavoletti et al., “Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings,” Journal of Nuclear Medicine, vol. 49, MeetingAbstracts_1, no. 5, p. 34, 2008. View at Google Scholar
  30. E. H. Corder, A. M. Saunders, W. J. Strittmatter et al., “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families,” Science, vol. 261, no. 5123, pp. 921–923, 1993. View at Google Scholar
  31. R_Development_Core_Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2013.
  32. Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate - a practical and powerful approach to multiple testing,” Journal of Royal Statistical Society B Methodological, vol. 57, no. 1, pp. 289–300, 1995. View at Google Scholar
  33. J. Sevigny, P. Chiao, T. Bussière et al., “The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease,” Nature, vol. 537, no. 7618, pp. 50–56, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Vellas, M. C. Carrillo, C. Sampaio et al., “Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD task force,” Alzheimer's & Dementia, vol. 9, no. 4, pp. 438–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Braak and E. Braak, “Frequency of stages of Alzheimer-related lesions in different age categories,” Neurobiology of Aging, vol. 18, no. 4, pp. 351–357, 1997. View at Google Scholar
  36. C. M. Hulette, K. A. Welsh-Bohmer, M. G. Murray, A. M. Saunders, D. C. Mash, and L. M. McIntyre, “Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals,” Journal of Neuropathology and Experimental Neurology, vol. 57, no. 12, pp. 1168–1174, 1998. View at Google Scholar
  37. W. R. Markesbery, “Neuropathologic alterations in mild cognitive impairment: a review,” Journal of Alzheimers Disease, vol. 19, no. 1, pp. 221–228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. W. R. Markesbery, F. A. Schmitt, R. J. Kryscio, D. G. Davis, C. D. Smith, and D. R. Wekstein, “Neuropathologic substrate of mild cognitive impairment,” Archives of Neurology-Chicago, vol. 63, no. 1, pp. 38–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. C. Morris and J. L. Price, “Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease,” Journal of Molecular Neuroscience, vol. 17, no. 2, pp. 101–118, 2001. View at Google Scholar
  40. J. L. Price, A. I. Ko, M. J. Wade, S. K. Tsou, D. W. McKeel, and J. C. Morris, “Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease,” Archives of Neurology-Chicago, vol. 58, no. 9, pp. 1395–1402, 2001. View at Google Scholar
  41. T. GomezIsla, J. L. Price, D. W. McKeel, J. C. Morris, J. H. Growdon, and B. T. Hyman, “Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease,” Journal of Neuroscience, vol. 16, no. 14, pp. 4491–4500, 1996. View at Google Scholar
  42. H. Wilhelm and B. Wilhelm, “Clinical applications of pupillography,” Journal of Neuro-Ophthalmology, vol. 23, no. 1, pp. 42–49, 2003. View at Google Scholar
  43. B. Dubois, B. Pillon, F. Lhermitte, and Y. Agid, “Cholinergic deficiency and frontal dysfunction in Parkinson’s disease,” Annals of Neurology, vol. 28, no. 2, pp. 117–121, 1990. View at Publisher · View at Google Scholar · View at Scopus